ALDER BIOPHARMACEUTICALS INC
ALDR evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Lead Asset:
- ald1910 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ALDR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
ald1910 (Preclinical)
Next Catalyst
—
Tracking 2 pipeline candidates · 1 clinical trial for ALDER BIOPHARMACEUTICALS INC.
Run ALDER BIOPHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ALDER BIOPHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is ALDER BIOPHARMACEUTICALS INC's lead drug candidate?
ALDER BIOPHARMACEUTICALS INC's most advanced tracked candidate is ald1910 (Preclinical) for migraine.
Who is the CEO of ALDER BIOPHARMACEUTICALS INC?
Paul B. Cleveland is the chief executive officer of ALDER BIOPHARMACEUTICALS INC (ALDR).
What therapeutic areas does ALDER BIOPHARMACEUTICALS INC focus on?
ALDER BIOPHARMACEUTICALS INC develops therapies across Neurology, Immunology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.